National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 60893-60894 [2021-24029]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 211 / Thursday, November 4, 2021 / Notices
Public Health Advisor, Indian Health
Service, Division of Behavioral Health,
5600 Fishers Lane, Mail Stop: 08N70C,
Rockville, MD 20857, Telephone: (240)
252–9625, Fax: (301) 443–5610, Email:
Monique.Richards@ihs.gov.
2. Questions on grants management
and fiscal matters may be directed to:
Sheila Miller, Grants Management
Specialist, Indian Health Service,
Division of Grants Management, 5600
Fishers Lane, Mail Stop: 09E70,
Rockville, MD 20857, Phone: (240) 535–
9308, Fax: (301) 594–0899, Email:
Sheila.Miller@ihs.gov.
3. Questions on systems matters may
be directed to: Paul Gettys, Acting
Director, Division of Grants
Management, Indian Health Service,
Division of Grants Management, 5600
Fishers Lane, Mail Stop: 09E70,
Rockville, MD 20857, Phone: (301) 443–
2114; or the DGM main line (301) 443–
5204, Fax: (301) 594–0899, email:
Paul.Gettys@ihs.gov.
VIII. Other Information
The Public Health Service strongly
encourages all grant, cooperative
agreement, and contract recipients to
provide a smoke-free workplace and
promote the non-use of all tobacco
products. In addition, Public Law 103–
227, the Pro-Children Act of 1994,
prohibits smoking in certain facilities
(or in some cases, any portion of the
facility) in which regular or routine
education, library, day care, health care,
or early childhood development
services are provided to children. This
is consistent with the HHS mission to
protect and advance the physical and
mental health of the American people.
Elizabeth A. Fowler,
Acting Director, Indian Health Service.
[FR Doc. 2021–24039 Filed 11–3–21; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute of Neurological
Disorders and Stroke; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Neurological Disorders and Stroke
Council.
The meeting will be open to the
public. Individuals who plan to
participate and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
VerDate Sep<11>2014
17:57 Nov 03, 2021
Jkt 256001
should notify the Contact Person listed
below in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Neurological Disorders and Stroke Council.
Date: November 29, 2021.
Open: November 29, 2021, 1:00 p.m. to
2:00 p.m.
Agenda: Concept clearance of proposed
initiatives.
Open session will be videocast from this
link: https://videocast.nih.gov/.
Closed: November 29, 2021, 2:00 p.m. to
4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Rockville, MD 20852 (Virtual Meeting).
Contact Person: Robert Finkelstein, Ph.D.,
Director of Extramural Research, National
Institute of Neurological Disorders and
Stroke, NIH, 6001 Executive Blvd., Suite
3309, MSC 9531, Rockville, MD 20852, (301)
496–9248, finkelsr@ninds.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice at least 10 days in advance of the
meeting. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.ninds.nih.gov, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: October 29, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–23999 Filed 11–3–21; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
60893
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Diabetes Self-Care.
Date: November 15, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 29892 (Telephone
Conference Call).
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–8886,
sanoviche@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Wearable Devices.
Date: November 16, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–8886,
sanoviche@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
E:\FR\FM\04NON1.SGM
04NON1
60894
Federal Register / Vol. 86, No. 211 / Thursday, November 4, 2021 / Notices
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 29, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24029 Filed 11–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Fogarty HIV Research Training Program for
Low- and Middle-Income Country
Institutions.
Date: December 2–3, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maureen Shuh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–480–4097,
maureen.shuh@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Genes, Genomes and Genetics.
Date: December 6, 2021.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elena Smirnova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5187,
MSC 7840, Bethesda, MD 20892, 301–357–
9112, smirnove@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics
Focused on Alzheimer’s Disease and
Alzheimer’s-Related Dementia.
VerDate Sep<11>2014
17:57 Nov 03, 2021
Jkt 256001
Date: December 7–8, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tara Roshell Earl, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007C,
Bethesda, MD 20892, (301) 451–3946, earltr@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory Sciences.
Date: December 13–14, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ghenima Dirami, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122,
MSC 7814, Bethesda, MD 20892, (240) 498–
7546, diramig@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 31, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24053 Filed 11–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., 301–496–2644;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
SUMMARY:
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Recombinant Chimeric Bovine/Human
Parainfluenza Virus 3 Expressing
SARS–CoV–2 Spike Protein and Its Use
Description of Technology
Vaccines for SARS–CoV–2 are
increasingly available under emergency
use authorizations; however, indications
are currently limited to individuals
twelve (12) years or older. They also
involve intramuscular immunization,
which does not directly stimulate local
immunity in the respiratory tract, the
primary site of SARS–CoV–2 infection,
shedding and spread. While the major
burden of COVID–19 disease is in
adults, infection and disease also occur
in infants and young children,
contributing to viral transmission.
Therefore, the development of safe and
effective pediatric COVID–19 vaccines
is important. Ideally, a vaccine should
be effective as a single dose, should
induce mucosal immunity with the
ability to restrict SARS–CoV–2 infection
and respiratory shedding, and should
easily coordinate with vaccines for other
illnesses, such as HPIV3.
The live-attenuated vaccine
candidates are based on a recombinant
chimeric bovine/human parainfluenza
virus 3 (rB/HPIV3) vector expressing
prefusion-stabilized versions of the
Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS–CoV–2) Spike (S)
protein. The B/HPIV3–SARS CoV–2
vaccine candidates are designed to be
administered intranasally by drops or
spray to infants and young children.
The vaccines are expected to induce
durable and broad systemic and
respiratory mucosal immunity against
SARS–CoV–2 and HPIV3.
Immunogenicity and protective efficacy
against SARS–CoV–2 challenge was
confirmed in experimental animals
including non-human primates. Based
on experience with this B/HPIV3
platform and other live-attenuated PIV
vaccine candidates in previous pediatric
clinical studies, the present candidates
are anticipated to be well-tolerated in
humans, including infants and young
children, and are available for clinical
evaluation. The National Institute of
Allergy and Infectious Diseases has
extensive experience and capability in
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 86, Number 211 (Thursday, November 4, 2021)]
[Notices]
[Pages 60893-60894]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24029]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Diabetes Self-Care.
Date: November 15, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 29892 (Telephone Conference Call).
Contact Person: Elena Sanovich, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-
594-8886, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Wearable Devices.
Date: November 16, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Elena Sanovich, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-
594-8886, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
[[Page 60894]]
and Hematology Research, National Institutes of Health, HHS)
Dated: October 29, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-24029 Filed 11-3-21; 8:45 am]
BILLING CODE 4140-01-P
